Aubex Therapeutics Launches to Revolutionize Cancer Treatment with Novel Compounds directed toward the Tumor Microenvironment

SAN DIEGO--(BUSINESS WIRE)--Aubex Therapeutics Inc., a pioneering biotechnology firm, today announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex’s initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment (TME). Aubex’s R&D program shows promise, particularly in cancers wher